Acne Keloidalis Nuchae Successfully Treated with Halobetasol 0.01% and Tazarotene 0.045% Lotion

Main Article Content

Olga Marushchak
Department of Dermatology, Icahn School of Medicine at Mount Sinai
https://orcid.org/0000-0001-8858-5987
Kathryn Jayne Tan
Icahn School of Medicine at Mount Sinai Hospital

Maria Rosa Noliza Encarnacion
Icahn School of Medicine at Mount Sinai Hospital

Loren Clark
Touro College of Osteopathic Medicine

Alexandra Golant
Icahn School of Medicine at Mount Sinai Hospital

Keywords

acne keloidalis nuchae, halobetasol/tazarotene lotion

Abstract

Acne keloidalis nuchae (AKN) is an idiopathic chronic inflammatory condition that predominantly affects African-American men and presents with follicular papules, pustules and plaques, which may eventually lead to keloid-like scarred lesions, fibrotic plaques, abscesses, sinuses, and alopecia. Conventional treatment approach focuses on avoidance of exacerbation factors, utilization of topical and oral antibiotics, and decreasing inflammation with intralesional steroids. This is the first case showing successful treatment of AKN with halobetasol 0.01% and tazarotene 0.045% lotion. Although topical steroids and topical retinoids have been used as treatment options, there are no published data supporting the use of their fixed combination in patients with AKN.

References

1. Otberg N, Shapiro J. Cicatricial Alopecias. In: Kang S, Amagai M, Bruckner AL, Enk AH, Margolis DJ, McMichael AJ, Orringer JS. eds. Fitzpatrick's Dermatology, 9e. McGraw-Hill; Accessed February 12, 2021.

2. Maranda EL, Simmons BJ, Nguyen AH, Lim VM, Keri JE. Treatment of Acne Keloidalis Nuchae: A Systematic Review of the Literature. Dermatol Ther. 2016;6(3):363–378. doi:10.1007/s13555-016-0134-5

3. Sperling LC, Homoky C, Pratt L, Sau P. Acne Keloidalis Is a Form of Primary Scarring Alopecia. Arch Dermatol. 2000;136(4):479–484. doi:10.1001/archderm.136.4.479

4. Callender VD, Young CM, Haverstock CL, Carroll CL, Feldman SR. An open label study of clobetasol propionate 0.05% and betamethasone valerate 0.12% foams in the treatment of mild to moderate acne keloidalis. Cutis. 2005 Jun;75(6):317-21 PMID: 16047868.

5. Ogunbiyi A. Acne keloidalis nuchae: prevalence, impact, and management challenges. Clin Cosmet Investig Dermatol. 2016 Dec;9:483-489. doi:10.2147/CCID.S99225

6. Beckett N, Lawson C, Cohen G. Electrosurgical excision of acne keloidalis nuchae with secondary intention healing. J Clin Aesthet Dermatol. 2011 Jan;4(1):36-39

7. Esmat SM, Abdel Hay RM, Abu Zeid OM, Hosni HN. The efficacy of laser-assisted hair removal in the treatment of acne keloidalis nuchae; a pilot study. Eur J Dermatol. 2012;22(5):645-650. doi:10.1684/ejd.2012.1830

8. Dragoni F, Bassi A, Cannarozzo G, Bonan P, Moretti S, Campolmi P. Successful treatment of acne keloidalis nuchae resistant to conventional therapy with 1064-nm ND:YAG laser. G Ital Dermatol Venereol. 2013;148(2):231-232.

9. Shah GK. Efficacy of diode laser for treating acne keloidalis nuchae. Indian J Dermatol Venereol Leprol. 2005;71(1):31-34. doi:10.4103/0378-6323.13783

10. Okoye GA, Rainer BM, Leung SG, et al. Improving acne keloidalis nuchae with targeted ultraviolet B treatment: a prospective, randomized, split-scalp comparison study. Br J Dermatol. 2014;171(5):1156-1163. doi:10.1111/bjd.13119

11. Millán-Cayetano JF, Repiso-Jiménez JB, Del Boz J, de Troya-Martín M. Refractory acne keloidalis nuchae treated with radiotherapy. Australas J Dermatol. 2017;58(1):e11-e13. doi:10.1111/ajd.12380

12. Gloster HM Jr. The surgical management of extensive cases of acne keloidalis nuchae. Arch Dermatol. 2000;136(11):1376-1379. doi:10.1001/archderm.136.11.1376

Article Sidebar

PDF
Published
Jul 7, 2022
DOI https://doi.org/10.25251/skin.6.4.6

Article Details

How to Cite
Marushchak, O., Tan, K. J. ., Encarnacion, M. R. N. ., Clark, L., & Golant, A. (2022). Acne Keloidalis Nuchae Successfully Treated with Halobetasol 0.01% and Tazarotene 0.045% Lotion. SKIN The Journal of Cutaneous Medicine, 6(4), 311–314. https://doi.org/10.25251/skin.6.4.6
Issue
Vol. 6 No. 4 (2022): July 2022 Issue
Section
Brief Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.